Format

Send to

Choose Destination
J Diet Suppl. 2017 Mar 4;14(2):191-199. Epub 2016 Aug 11.

A Double-Blind, Randomized Pilot Trial of Chromium Picolinate for Overweight Individuals with Binge-Eating Disorder: Effects on Glucose Regulation.

Author information

1
a Department of Psychiatry , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA.
2
b Department of Psychology , Southern Methodist University , Dallas , TX , USA.
3
c Department of Psychology , George Mason University , Fairfax , VA , USA.
4
d Department of Nutrition , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA.
5
e Department of Medical Epidemiology and Biostatistics , Karolinska Institutet , Stockholm , Sweden.

Abstract

PURPOSE:

Chromium treatment has been shown to improve glucose regulation in some populations. The purpose of this study was to evaluate whether chromium picolinate (CrPic) supplementation improves glucose regulation in overweight individuals with binge-eating disorder (BED).

METHODS:

In this double-blinded randomized pilot trial, participants (N = 24) were randomized to high (HIGH, 1000 mcg/day, n = 8) or moderate (MOD, 600 mcg/day, n = 9) dose of CrPic or placebo (PL, n = 7) for 6 months. Participants completed an oral glucose tolerance test (OGTT) at baseline, 3 months, and 6 months. Fixed effects models were used to estimate mean change in glucose area under the curve (AUC), insulinAUC, and insulin sensitivity index (ISI).

RESULTS:

Results revealed a significant group and time interaction (p < 0.04) for glucoseAUC, with glucoseAUC increasing significantly in the PL group (p < 0.02) but decreasing significantly in the MOD group (p < 0.03) at 6 months. InsulinAUC increased significantly over time (main effect, p < 0.02), whereas ISI decreased significantly over time (main effect, p < 0.03).

CONCLUSION:

As anticipated, a moderate dose of CrPic was associated with improved glycemic control, whereas PL was associated with decreased glycemic control. It was unexpected that the improved glycemic control seen in the MOD dose group was not seen in the HIGH dose group. However, although participants randomized to the HIGH dose group did not have improved glycemic control, they had better glycemic control than participants randomized to the PL group. These findings support the need for larger trials.

KEYWORDS:

alternative medicine; binge-eating disorder; chromium; glucose

PMID:
27835050
DOI:
10.1080/19390211.2016.1207124
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center